Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420
Last updated 2026-03-12
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Non-Small Cell Lung Cancer
- NSCLC
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
- DRUG
-
oral tablets
- DRUG
-
intravenous (IV) infusion
Sponsors & Collaborators
-
Revolution Medicines, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-06
- Primary Completion
- 2027-12-01
- Completion
- 2030-12-01
- FDA Drug
- Yes
Countries
- United States
- Australia
- Belgium
- France
- Germany
- Hong Kong
- Ireland
- Italy
- Japan
- Netherlands
- New Zealand
- Poland
- Puerto Rico
- Singapore
- South Korea
- Spain
- Switzerland
- Taiwan
- United Kingdom
Study Locations
More Related Trials
-
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
NCT00617656 ·Status: TERMINATED ·Phase: PHASE3
-
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
NCT00760929 ·Status: TERMINATED ·Phase: PHASE2
-
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
NCT03061812 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
NCT00037817 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
NCT04267237 ·Status: WITHDRAWN ·Phase: PHASE2
-
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
NCT04697446 ·Status: UNKNOWN
-
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
NCT00461110 ·Status: TERMINATED ·Phase: PHASE1
-
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
NCT00903942 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02974725 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
NCT00606502 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
NCT01328951 ·Status: COMPLETED ·Phase: PHASE3
-
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
NCT00099879 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
NCT06532032 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
NCT00723957 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
NCT06855771 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759 ·Status: COMPLETED ·Phase: PHASE2
-
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
NCT05313009 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356 ·Status: RECRUITING ·Phase: PHASE3
-
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402 ·Status: RECRUITING ·Phase: PHASE1
-
Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)
NCT01424709 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00651508 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
NCT06008353 ·Status: ACTIVE_NOT_RECRUITING
-
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
NCT07249879 ·Status: RECRUITING ·Phase: PHASE1